Sopan Pharmaceuticals Reports 82 Percent Profit Decline in Fourth Quarter

3rd September 2026, Kathmandu

Sopan Pharmaceuticals Limited has reported a sharp decline in profitability for the fourth quarter of fiscal year 2082/83 with net profit falling by approximately 82 percent year on year due to surging production costs and unadjusted medicine pricing.

Sopan Pharmaceuticals Profit Decline

Financial Performance and Balance Sheet Overview

Net Profit Decline: The company earned a net profit of 38.289 million rupees for the review period compared to 217.791 million rupees in the corresponding period of the previous fiscal year.

Operating Income Growth: Operating revenue saw a slight increase rising to 511.472 million rupees from 500.531 million rupees recorded in the prior fiscal year.

Earnings Per Share: Earnings per share dropped sharply to 2.23 rupees from 18.33 rupees in the previous fiscal year.

Advertisement

Capital Base and Reserves: Paid up capital stands at 1.716 billion rupees with a reserve fund of 367.312 million rupees and net worth per share at 121.34 rupees.

Cost Pressures and Market Expansion Plan

Inflationary Factors: Profit margins were squeezed by the appreciation of the US dollar alongside higher raw material and fuel costs driven by regional conflict.

Price Constraints: The inability to adjust retail medicine prices in line with rising production overheads directly eroded overall profitability.

Future Outlook: The company plans to introduce new pharmaceutical product lines targeting cardiovascular, diabetes, and urological conditions while establishing a dedicated marketing division and optimizing inventory management to cut costs.

For More: Sopan Pharmaceuticals Profit Decline